| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $42.0M | -31.2% | +18.2% |
| SG&A Expense | $13.6M | -7.7% | +2.1% |
| Operating Income | -$55.6M | +26.7% | -13.8% |
| Net Income | -$50.6M | +27.8% | -24.8% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $103.3M | +41.9% | +1.2% |
| Short-term Investments | $229.3M | +19.0% | -51.8% |
| Current Assets | $342.2M | +24.0% | -42.2% |
| Total Assets | $484.1M | -7.0% | -25.9% |
| Current Liabilities | $32.8M | +16.7% | +35.3% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$137.6M | — | — |
| Capital Expenditures | $38K | — | — |
| Investing Cash Flow | $157.6M | — | — |
| Financing Cash Flow | $373K | — | — |
| Free Cash Flow | -$137.7M | — | — |
| $32.8M |
| +16.2% |
| +29.0% |
| Stockholders' Equity | $451.4M | -8.3% | -28.1% |